These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Activation of tumor-cytostatic macrophages with the antitumor agent 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazole-2-yl)hydrazone] dihydrochloride (bisantrene).
    Author: Wang BS, Lumanglas AL, Ruszala-Mallon VM, Durr FE.
    Journal: Cancer Res; 1984 Jun; 44(6):2363-7. PubMed ID: 6426780.
    Abstract:
    An investigation was carried out to determine the potential for activating tumor-inhibitory macrophages with the cytotoxic antitumor agent, bisantrene. Macrophages prepared from peritoneal exudates of mice treated i.p. with bisantrene were extremely active in inhibiting the growth of tumor cells. The minimal effective in vivo dose of this drug appeared to be 25 mg/kg, with peak activation being achieved at doses of 50 to 100 mg/kg. Effector cells became detectable 2 days after treatment and persisted for at least 4 weeks. Incubation of effector and target cells for 48 hr seemed necessary to achieve the maximum inhibitory effect. Treatment with carrageenan in vitro and in vivo abolished tumor cytostasis, whereas treatment with anti-T-cell antibody plus complement had no effect, suggesting that macrophages rather than T-lymphocytes were responsible for the observed results. Culture supernatants of activated macrophages were found to have antiproliferative effects on tumor cells, indicating that a cytostatic factor(s) was produced by these macrophages. Hydrogen peroxide and neutral proteases apparently did not function as cytostatic mediators since activated macrophages were resistant to treatment with catalase, N-alpha-p-tosyl-L-lysine chloromethyl ketone, and aprotinin. The present findings suggest that, in addition to direct toxicity to tumor cells, bisantrene may act as a macrophage-activating immunopotentiator. This observation may be of potential clinical usefulness in the design of immunochemotherapeutic trials for certain types of cancer.
    [Abstract] [Full Text] [Related] [New Search]